Prostate Cancer | Specialty

ADT in Prostate Cancer: Agonists Versus Antagonists

February 13th 2015

Integrating Molecular Testing Into Urology Practices

February 13th 2015

Biomarkers for Aiding Risk Stratification and Treatment Decisions

February 13th 2015

Follow-up Biomarker Testing in Prostate Cancer

February 13th 2015

Strategies for Using Biomarkers in Prostate Cancer

February 13th 2015

Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer

February 10th 2015

Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.

Dr. Mark Delworth on Robotic Prostatectomy

February 9th 2015

Mark Delworth, MD, a urologist and the medical director of the Minimally Invasive and Robotic Surgery Program at TriHealth Hospital, talks about the outcomes of robotic surgery for the treatment of prostate cancer.

Clinical and Economic Impact of Gene Expression Testing in Localized Prostate Cancer

February 4th 2015

Biopsy-based cell cycle progression gene expression testing can aid in the stratification of patients with localized prostate cancer based on disease aggressiveness.

Latest News & Insight: January 31, 2015

January 31st 2015

Dr. Taneja on MRI for Prostate Cancer Detection

January 30th 2015

Samir Taneja, MD, professor of Urology and Radiology and director of the Division of Urologic Oncology at NYU Langone Medical Center.

Dr. Tward on Abbreviated Course ADT for Prostate Cancer

January 23rd 2015

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.

Two Studies Explore Role of Radiation, Bisphosphonates in Prostate Cancer Care

January 19th 2015

For older men with prostate cancer, adding radiation to hormone therapy is both tolerable and effective in reducing the number of deaths.

Dendreon Revenue Rises, Despite Restructuring

January 14th 2015

Increased utilization of the autologous cellular immunotherapy sipuleucel-T (Provenge) led to a $20.1 million improvement in total revenue in 2014 for the manufacturer Dendreon, when compared with 2013.

Should a Lower-Grade Prostate Tumor Be Called Cancer?

January 9th 2015

For some insight on this discussion, OncLive sat down with prostate cancer expert and president-elect of SUO, Leonard G. Gomella, MD.

Dr. Sieber on the CHAARTED Trial

January 8th 2015

Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.

Medicare Reimburses 3 Prostate Cancer Diagnostic Tests

January 4th 2015

After months of delay, the Medicare Administrative Contractor (MAC), with jurisdiction over most molecular diagnostic tests used to treat cancer, made a series of decisions this fall that will allow Medicare reimbursement for several well-known tests, including 3 used in the treatment of prostate cancer.

Gene Points to Aggressive Gleason 7 Prostate Cancer

December 31st 2014

A biomarker has been found that may help determine which Gleason 7 (GS7) cancers are particularly aggressive.

There's No Place Like a Medical Home: Premier Medical Group Focuses on Full-scale Patient-Centered Care

December 28th 2014

It's not uncommon for a business to use a superlative in its name, but Premier Medical Group in Poughkeepsie, NY, truly lives up to its moniker.

No Salvage Treatment for Some With PSA Recurrence

December 27th 2014

One-third of men over 70 years of age who undergo radical prostatectomy for prostate cancer and then experience biochemical recurrence have no need for salvage treatment, according to a recent study.

Dr. Gomella on Labeling Low-Risk Prostate Cancer

December 26th 2014

Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.